Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2007, p. 3036-3037, Vol. 51, No. 8
0066-4804/07/$08.00+0 doi:10.1128/AAC.00357-07
Interdomain Loop Mutation Asp190Cys of the Tetracycline Efflux Transporter TetA(B) Decreases Affinity for Substrate

LETTER
TetA(B), the tetracycline efflux protein from Tn
10, has 12 predicted

-helices that span the
Escherichia coli cytoplasmic membrane
(
10) and is a member of the major facilitator superfamily (
4).
TetA(B) and related tetracycline antiporters use the bacterial
transmembrane proton motive force to export one metal-tetracycline
complex in exchange for one H
+ (
12), thereby reducing the intracellular
tetracycline concentration.
In our recent studies of the cytoplasmic interdomain loop connecting transmembrane helices 6 and 7 of TetA(B) (7) and TetA(C) (6), we showed that this loop contains residues implicated in tetracycline efflux activity. Furthermore, we established that residues Asp190, Glu192, and Ser201 of TetA(B) are involved in substrate specificity of the pump (7). Mutations of three adjacent amino acids in the interdomain loop of TetA(A) in two veterinary Salmonella isolates showed an altered substrate specificity with reduced susceptibility to minocycline and glycylcyclines (11). In the present work, we investigated the basis for the effect of the Asp190Cys mutation on tetracycline efflux mediated by TetA(B) in everted membrane vesicles using [H3]tetracycline.
The low-copy plasmids (origin of replication pSC101) that specified the Asp190Cys mutation (7) and wild-type TetB (13) were transformed into Escherichia coli DH5
; everted membrane vesicles were prepared as described previously (3). The protein content was quantified using the bicinchoninic acid protein assay (Pierce, Rockford, IL), and vesicle aliquots were stored in 50 mM MOPS (morpholinepropanesulfonic acid), pH 6.6, at –80°C. The antiport activity of vesicles was verified by an acridine orange fluorescence method. The amount of TetA(B) protein in the membranes was also determined by Western immunoblotting using anti-Ct antibody as described previously (7) and showed the same amount in each strain.
Graphpad prism 4 software was used to determine the Km and Vmax values by fitting to the Michaelis-Menton equation. The cysteine substitution for aspartate at position 190 showed an average Km value 3.8 times that of the wild type but did not produce any modification in Vmax (Table 1). The Km and Vmax values obtained for the wild type are in agreement with those reported in the literature (3, 8, 9, 14). The lower affinity for tetracycline of the mutant Asp190Cys suggests that the aspartate residue is involved in the substrate interaction. Possibly the negatively charged aspartate interacts with the positively charged divalent metal cation-tetracycline complex which is the substrate. That a substitution causing a change in Km of a protein indicates a position involved in substrate binding has been shown with the ß-lactamase TEM1 (1, 2).
View this table:
[in this window]
[in a new window]
|
TABLE 1. Tetracycline resistance levels of E. coli DH5 cells with and without plasmid-borne wild-type and mutant TetA(B) and Km and Vmax for tetracycline uptake by everted membrane vesicles
|
Although Asp190 is not an essential residue for tetracycline
efflux (
10), we show clearly that changing it to Cys lowered
the affinity (higher
Km) of the pump for its substrate. The
sequence of the approximately 30 amino acids comprising the
cytoplasmic interdomain loop is not conserved among the dozen
or so related tetracycline efflux pumps (
5). This loop has been
assumed until recently to be simply a tether holding the two
halves of the protein together. Our biochemical results now
support previous data in vivo that this loop of TetA(B) has
an unexpected role in tetracycline transport.

ACKNOWLEDGMENTS
F.M.S. was supported by a Fellowship of the Belgian American
Educational Foundation (BAEF). This work was supported by National
Institutes of Health grant GM55430 to S.B.L.
We thank Laura McMurry for helpful comments on the manuscript.

FOOTNOTES

Published ahead of print on 21 May 2007.

Present address: Centre d'Ingénierie des Protéines, Université de Liège, Institut de Chimie, B-4000 Liège, Belgium. 

REFERENCES
1 - Dubus, A., J. M. Wilkin, X. Raquet, S. Normark, and J. M. Frere. 1994. Catalytic mechanism of active-site serine beta-lactamases: role of the conserved hydroxy group of the Lys-Thr(Ser)-Gly triad. Biochem. J. 301:485-494.[Medline]
2 - Fonze, E., P. Charlier, Y. To'th, M. Vermeire, X. Raquet, A. Dubus, and J. M. Frere. 1995. TEM1 beta-lactamase structure solved by molecular replacement and refined structure of the S235A mutant. Acta Crystallogr. Sect. D 51:682-694.[CrossRef][Medline]
3 - McMurry, L., R. E. Petrucci, Jr., and S. B. Levy. 1980. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc. Natl. Acad. Sci. USA 77:3974-3977.[Abstract/Free Full Text]
4 - Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.[Abstract/Free Full Text]
5 - Sapunaric, F. M., M. L. Aldema-Ramos, and L. M. McMurry. 2005. Tetracycline resistance: efflux, mutation, and other mechanisms, p. 3-18. In D. G. White, M. N. Alekshun, and P. F. McDermott (ed.), Frontiers in antimicrobial resistance: a tribute to Stuart B. Levy. ASM Press, Washington, DC.
6 - Sapunaric, F. M., and S. B. Levy. 2003. Second-site suppressor mutations for the serine 202 to phenylalanine substitution within the interdomain loop of the tetracycline efflux protein Tet(C). J. Biol. Chem. 278:28588-28592.[Abstract/Free Full Text]
7 - Sapunaric, F. M., and S. B. Levy. 2005. Substitutions in the interdomain loop of the Tn10 TetA efflux transporter alter tetracycline resistance and substrate specificity. Microbiology 151:2315-2322.[Abstract/Free Full Text]
8 - Someya, Y., T. Kimura-Someya, and A. Yamaguchi. 2000. Role of the charge interaction between Arg(70) and Asp(120) in the Tn10-encoded metal-tetracycline/H(+) antiporter of Escherichia coli. J. Biol. Chem. 275:210-214.[Abstract/Free Full Text]
9 - Someya, Y., and A. Yamaguchi. 1996. Mercaptide formed between the residue Cys70 and Hg2+ or Co2+ behaves as a functional positively charged side chain operative in the Arg70
Cys mutant of the metal-tetracycline/H+ antiporter of Escherichia coli. Biochemistry 35:9385-9391.[CrossRef][Medline] 10 - Tamura, N., S. Konishi, S. Iwaki, T. Kimura-Someya, S. Nada, and A. Yamaguchi. 2001. Complete cysteine-scanning mutagenesis and site-directed chemical modification of the Tn10-encoded metal-tetracycline/H+ antiporter. J. Biol. Chem. 276:20330-20339.[Abstract/Free Full Text]
11 - Tuckman, M., P. J. Petersen, and S. J. Projan. 2000. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. 6:277-282.[Medline]
12 - Yamaguchi, A., Y. Iwasaki-Ohba, N. Ono, M. Kaneko-Ohdera, and T. Sawai. 1991. Stoichiometry of metal-tetracycline/H+ antiport mediated by transposon Tn10-encoded tetracycline resistance protein in Escherichia coli. FEBS Lett. 282:415-418.[CrossRef][Medline]
13 - Yamaguchi, A., N. Ono, T. Akasaka, T. Noumi, and T. Sawai. 1990. Metal-tetracycline/H+ antiporter of Escherichia coli encoded by a transposon, Tn10. The role of the conserved dipeptide, Ser65-Asp66, in tetracycline transport. J. Biol. Chem. 265:15525-15530.[Abstract/Free Full Text]
14 - Yamaguchi, A., R. O'Yauchi, Y. Someya, T. Akasaka, and T. Sawai. 1993. Second-site mutation of Ala-220 to Glu or Asp suppresses the mutation of Asp-285 to Asn in the transposon Tn10-encoded metal-tetracycline/H+ antiporter of Escherichia coli. J. Biol. Chem. 268:26990-26995.[Abstract/Free Full Text]
| | | | | |
Frédéric M. Sapunaric
Stuart B. Levy*
Center for Adaptation Genetics and Drug Resistance Tufts University School of Medicine 136 Harrison Ave. Boston, MA 02111
|
| | | | | |
* Phone: (617) 636-6764 Fax: (617) 636-0458 E-mail: stuart.levy{at}tufts.edu |
Antimicrobial Agents and Chemotherapy, August 2007, p. 3036-3037, Vol. 51, No. 8
0066-4804/07/$08.00+0 doi:10.1128/AAC.00357-07